Distinct Uroplakin II Staining Pattern in Apocrine Breast Carcinoma.

Autor:	van Pel DM; Department of Pathology and Laboratory Medicine, University of British Columbia., Pors J; Department of Pathology and Laboratory Medicine, BC Cancer Vancouver Centre, Vancouver, BC, Canada., Yuen E; Department of Pathology and Laboratory Medicine, BC Cancer Vancouver Centre, Vancouver, BC, Canada., Chan R; Department of Pathology and Laboratory Medicine, BC Cancer Vancouver Centre, Vancouver, BC, Canada., Kos Z; Department of Pathology and Laboratory Medicine, University of British Columbia.; Department of Pathology and Laboratory Medicine, BC Cancer Vancouver Centre, Vancouver, BC, Canada., Hayes MM; Department of Pathology and Laboratory Medicine, University of British Columbia.; Department of Pathology and Laboratory Medicine, BC Cancer Vancouver Centre, Vancouver, BC, Canada., Wang G; Department of Pathology and Laboratory Medicine, University of British Columbia.; Department of Pathology and Laboratory Medicine, BC Cancer Vancouver Centre, Vancouver, BC, Canada.
Jazyk:	angličtina
Zdroj:	Applied immunohistochemistry & molecular morphology : AIMM [Appl Immunohistochem Mol Morphol] 2022 Nov-Dec 01; Vol. 30 (10), pp. 681-686. Date of Electronic Publication: 2022 Oct 14.
DOI:	10.1097/PAI.0000000000001072
Abstrakt:	Uroplakin II (UPII) has been shown as a highly specific marker of urothelial carcinoma; however, it can also stain subtypes of apocrine-differentiated breast carcinoma. Given that urothelium and breast epithelium share other common immunohistochemical markers, such as CK7 and GATA3, this can lead to a potential diagnostic pitfall. We stained a cohort of triple-negative breast cancer with UPII. Compared with the diffuse, cytoplasmic staining in urothelial carcinoma, UPII was positive in 38.9% of apocrine carcinoma (7/18) with a course, granular cytoplasmic staining pattern and negative in all nonapocrine triple-negative breast cancer cases. Furthermore, the same staining pattern was present in all apocrine metaplasia of the breast (4/4) and apocrine sweat glands in normal skin (6/6). This distinct subcellular localization of UPII staining in breast carcinoma can offer a potential solution to the above diagnostic pitfall. Competing Interests: The authors declare no conflicts of interests. (Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu